Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

The development of glutamate-based antidepressants is taking longer than expected.

Garay R, Zarate CA Jr, Cavero I, Kim YK, Charpeaud T, Skolnick P.

Drug Discov Today. 2018 Mar 1. pii: S1359-6446(17)30332-X. doi: 10.1016/j.drudis.2018.02.006. [Epub ahead of print] No abstract available.

PMID:
29501913
2.

Reminiscing about Jan Evangelista Purkinje: a pioneer of modern experimental physiology.

Cavero I, Guillon JM, Holzgrefe HH.

Adv Physiol Educ. 2017 Dec 1;41(4):528-538. doi: 10.1152/advan.00068.2017.

3.

15th Annual Meeting of the Safety Pharmacology Society: Focus on traditional sensory systems.

Cavero I, Holzgrefe H.

J Pharmacol Toxicol Methods. 2017 Jan - Feb;83:55-71. doi: 10.1016/j.vascn.2016.09.003. Epub 2016 Sep 19.

PMID:
27659846
4.

Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.

Cavero I, Guillon JM, Ballet V, Clements M, Gerbeau JF, Holzgrefe H.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:21-36. doi: 10.1016/j.vascn.2016.05.012. Epub 2016 May 24. Review.

PMID:
27233533
5.

Investigational drugs for treating agitation in persons with dementia.

Garay RP, Citrome L, Grossberg GT, Cavero I, Llorca PM.

Expert Opin Investig Drugs. 2016 Aug;25(8):973-83. doi: 10.1080/13543784.2016.1193155. Epub 2016 Jun 7. Review.

PMID:
27232589
6.

The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.

Cavero I, Holzgrefe H, Clements M.

J Pharmacol Toxicol Methods. 2016 Jul-Aug;80:1-8. doi: 10.1016/j.vascn.2016.02.181. Epub 2016 Mar 9.

PMID:
26903171
7.

14th Annual Meeting of the Safety Pharmacology Society: Threading through peripheral and central nervous system presentations.

Cavero I, Holzgrefe H.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:143-57. doi: 10.1016/j.vascn.2015.08.155. Epub 2015 Aug 22.

PMID:
26309091
8.

CiPA: Ongoing testing, future qualification procedures, and pending issues.

Cavero I, Holzgrefe H.

J Pharmacol Toxicol Methods. 2015 Nov-Dec;76:27-37. doi: 10.1016/j.vascn.2015.06.004. Epub 2015 Jul 6.

PMID:
26159293
9.

14th Annual Meeting of the Safety Pharmacology Society: threading through scientific sessions for originality and novelty.

Cavero I.

Expert Opin Drug Saf. 2015 Jun;14(6):999-1008. doi: 10.1517/14740338.2015.1034104. Epub 2015 Apr 15.

PMID:
25872620
10.

13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers.

Cavero I.

Expert Opin Drug Saf. 2014 Sep;13(9):1271-81. doi: 10.1517/14740338.2014.940310. Epub 2014 Jul 23.

PMID:
25054438
11.

Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.

Cavero I, Holzgrefe H.

Expert Opin Drug Saf. 2014 Jun;13(6):745-58. doi: 10.1517/14740338.2014.915311. Review.

PMID:
24845945
12.

Safety Pharmacology assessment of drugs with biased 5-HT(2B) receptor agonism mediating cardiac valvulopathy.

Cavero I, Guillon JM.

J Pharmacol Toxicol Methods. 2014 Mar-Apr;69(2):150-61. doi: 10.1016/j.vascn.2013.12.004. Epub 2013 Dec 19. Review.

PMID:
24361689
13.

2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines.

Cavero I.

Expert Opin Drug Saf. 2013 Jul;12(4):589-603. doi: 10.1517/14740338.2013.798300. Epub 2013 May 14.

PMID:
23668378
14.

2011 Annual Meeting of the Safety Pharmacology Society: an overview.

Cavero I.

Expert Opin Drug Saf. 2012 Mar;11(2):341-53. doi: 10.1517/14740338.2012.661412. Epub 2012 Feb 18.

PMID:
22339583
15.

10th annual meeting of the Safety Pharmacology Society: an overview.

Cavero I.

Expert Opin Drug Saf. 2011 Mar;10(2):319-33. doi: 10.1517/14740338.2011.555980. Epub 2011 Feb 14.

PMID:
21314442
16.

Safety Pharmacology Society: 9th Annual Meeting.

Cavero I.

Expert Opin Drug Saf. 2010 Mar;9(2):365-78. doi: 10.1517/14740331003625577.

PMID:
20175703
18.

Safety Pharmacology Society: 8th annual meeting.

Cavero I; Safety Pharmacology Society.

Expert Opin Drug Saf. 2009 Mar;8(2):237-47. doi: 10.1517/14740330902760360 .

PMID:
19309250
19.

Drug discovery paradigms: past, present, future - a centennial symposium of the American Society for Pharmacology and Experimental Therapeutics.

Cavero I, Kaplan HR.

Expert Opin Drug Discov. 2008 Sep;3(9):1145-54. doi: 10.1517/17460441.3.9.1145.

PMID:
23506185
20.

Safety Pharmacology Society: 7th annual meeting 19 - 20 September 2007, Edinburgh, UK.

Cavero I.

Expert Opin Drug Saf. 2008 Jan;7(1):91-100. doi: 10.1517/14740338.7.1.91 . No abstract available. Erratum in: Expert Opin Drug Saf. 2008 Mar;7(2):211.

PMID:
18171317
22.
23.

Analysis of the nonclinical telemetered ECG: impact of logging rate and RR bin width in the dog and cynomolgus monkey.

Holzgrefe HH, Cavero I, Gleason CR.

J Pharmacol Toxicol Methods. 2007 Jul-Aug;56(1):34-42. Epub 2006 Dec 20.

PMID:
17258913
24.

Simple-to-use, reference criteria for revealing drug-induced QT interval prolongation in conscious dogs.

Schmitt MW, Von Landenberg F, Poth H, Wimmer E, Goddemeier T, Cavero I.

Eur J Pharmacol. 2007 Jan 5;554(1):46-52. Epub 2006 Oct 10.

PMID:
17112506
25.

Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.

Holzgrefe HH, Cavero I, Buchanan LV, Gill MW, Durham SK.

J Pharmacol Toxicol Methods. 2007 May-Jun;55(3):227-37. Epub 2006 Sep 15.

PMID:
17097307
26.

Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys.

Holzgrefe HH, Cavero I, Gleason CR, Warner WA, Buchanan LV, Gill MW, Burkett DE, Durham SK.

J Pharmacol Toxicol Methods. 2007 Mar-Apr;55(2):159-75. Epub 2006 May 27.

PMID:
16857392
27.

Evaluation of the rabbit Purkinje fibre assay as an in vitro tool for assessing the risk of drug-induced torsades de pointes in humans.

Aubert M, Osterwalder R, Wagner B, Parrilla I, Cavero I, Doessegger L, Ertel EA.

Drug Saf. 2006;29(3):237-54.

PMID:
16524323
28.
29.

Safety Pharmacology Society: 5th annual meeting.

Cavero I, Crumb W.

Expert Opin Drug Saf. 2006 Jan;5(1):181-5.

PMID:
16370966
31.
32.

Patch-clamp studies of human cardiac ion channels in the evaluation of cardiac electrophysiological effects of compounds.

Crumb WJ, Cavero I.

Curr Protoc Pharmacol. 2003 May;Chapter 10:Unit10.8. doi: 10.1002/0471141755.ph1008s20.

PMID:
21956800
33.
34.

Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias.

Cavero I, Mestre M, Guillon JM, Crumb W.

Expert Opin Pharmacother. 2000 Jul;1(5):947-73. Review.

PMID:
11249502
35.

Frequency-independent blockade of cardiac Na+ channels by riluzole: comparison with established anticonvulsants and class I anti-arrhythmics.

Mestre M, Djellas Y, Carriot T, Cavero I.

Fundam Clin Pharmacol. 2000 Mar-Apr;14(2):107-17.

PMID:
10796057
36.

Avoiding adverse modification of cardiac repolarization.

Cavero I I, Towart I I.

Pharm Sci Technolo Today. 2000 Jan;3(1):5-6. No abstract available.

PMID:
10637594
37.

Preclinical in vitro cardiac electrophysiology: a method of predicting arrhythmogenic potential of antihistamines in humans?

Cavero I, Mestre M, Guillon JM, Heuillet E, Roach AG.

Drug Saf. 1999;21 Suppl 1:19-31; discussion 81-7. Review.

PMID:
10597865
38.

QT interval prolongation by non-cardiovascular drugs: issues and solutions for novel drug development.

Crumb W, Cavero I I.

Pharm Sci Technolo Today. 1999 Jul;2(7):270-280.

PMID:
10407390
39.
40.
41.

Preferential reduction in vascular responses to endothelin-1 in rats with streptozotocin-induced diabetes.

Guillon JM, Thiry C, Roach AG, Cavero I.

J Cardiovasc Pharmacol. 1998;31 Suppl 1:S133-7.

PMID:
9595421
42.

Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart.

Schultz JE, Yao Z, Cavero I, Gross GJ.

Am J Physiol. 1997 Jun;272(6 Pt 2):H2607-15.

PMID:
9227537
43.

The myocardial lesions produced by the potassium channel opener aprikalim in monkeys and rats are prevented by blockade of cardiac beta-adrenoceptors.

Belin V, Hodge T, Picaut P, Jordan R, Algate C, Gosselin S, Nohynek G, Cavero I.

Fundam Appl Toxicol. 1996 Jun;31(2):259-67.

PMID:
8789792
44.
45.

The arterial wall: a new pharmacological and therapeutic target.

Laurent S, Vanhoutte P, Cavero I, Chabrier PE, Dupuis B, Elghozi JL, Hamon G, Janiak P, Juillet Y, Kher A, Koen R, Madonna O, Maffrand JP, Pruneau D, Thuillez C.

Fundam Clin Pharmacol. 1996;10(3):243-57. Review.

PMID:
8836698
46.
47.

[Arterial wall: a new pharmacological and therapeutic target?].

Laurent S, Vanhoutte P, Cavero I, Chabrier PE, Dupuis B, Elghozi JL, Hamon G, Janiak P, Juillet Y, Kher A, et al.

Therapie. 1995 Jul-Aug;50(4):387-98. Review. French.

PMID:
7482394
49.

Effects of beta 2-adrenoceptor agonists on anti-IgE-induced contraction and smooth muscle reactivity in human airways.

Gorenne I, Labat C, Norel X, De Montpreville V, Guillet MC, Cavero I, Brink C.

Br J Pharmacol. 1995 Mar;114(5):935-40.

50.

Ischemic myocardial cell protection conferred by the opening of ATP-sensitive potassium channels.

Cavero I, Djellas Y, Guillon JM.

Cardiovasc Drugs Ther. 1995 Mar;9 Suppl 2:245-55. Review.

PMID:
7647029

Supplemental Content

Loading ...
Support Center